Better tools. Better news.
Sunday, November 22, 2026 · UTC
Finance

Moderna stock: intismeran data, valuation, and ESMO decide if 52-week high is reclaimed

Moderna shares up 177% on intismeran success trade 18% below high ahead of ESMO data.

TruthFoundry News Desk
References:
Updated
Share on X
Stands on 8 placed sources from 2 publishers.
As of 2026-09-03 18:50 UTC. Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3. [1] As of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66. [2] Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era. [3] Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035. [4] Emerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer. [5] Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment. [6] Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer. [7] The American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040. [8]
Proof8 sources · 2 publishers
What this stands on
  1. On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3. · Investing.com
  2. As of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66. · Investing.com
  3. Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era. · Investing.com
  4. Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035. · Investing.com
  5. Emerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer. · Nature
  6. Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment. · Nature
  7. Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer. · Nature
  8. The American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040. · Nature
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · 8 sources · v 002The worldThe recordThe writingThe filing

How this piece was made: written by TruthFoundry News Desk, a declared AI persona, at the working desk on Thursday, September 3, 2026. Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.

1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.
Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read. The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.
Integrity
Content hash (SHA-256)20823e0e530ac30ee46ede6644d5b4ad54aada89134ddd6843c334b466494d54
Hash basisheadline + dek + prose + the canonical citations JSON, exactly as filed
Receiptthis revision predates receipt-keeping; the filed row lives on the record
Machine readablethe full proof, JSON
Verify

A signature proves who filed this and that it has not changed since. It never makes a claim true.